Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review
DOI:
https://doi.org/10.2340/1651-226X.2025.42109Keywords:
late effects, CIPN, TIPN, Neurotoxicity, Delayed Onset, Cancer chemotherapyAbstract
Background and purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose limiting adverse effect that may be transient or become persistent after the treatment ended. The taxane paclitaxel induces CIPN in 57–83% of patients treated. The neuropathy may debut or progress after the end of treatment (EOT), known as coasting, but little is known about the incidence of this phenomenon. The aim of this review is to examine the incidence and severity of coasting in CIPN in patients with breast cancer.
Patient/material and methods: MEDLINE, Embase, clinicaltrials.gov, and medrivx.org were searched using terms related to taxanes, adverse effects, and breast cancer. Studies had to have a follow-up time of at least 3 months after EOT and patients had to have received taxanes in monotherapy. Additionally, studies had to be longitudinal and describe the neuropathy assessment method and timing.
Results: A total of 17 studies met the eligibility criteria, with 4,265 participants summarized. Of these, one study reported coasting events in 14.3% (n = 4) of patients. Eight studies reported no coasting events and eight were unclear.
Interpretation: Few studies reported on coasting in CIPN. There may be several reasons for this, including the timing and choice of assessment methods, confounding factors, and the possible rarity of the phenomenon. More information is needed about coasting in CIPN to better characterize the neuropathies, guide patient and doctor decisions, and aid in the development of interventions toward CIPN.
Downloads
References
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neu-ropathy: a current review. Ann Neurol. 2017;81(6):772–81.
https://doi.org/10.1002/ana.24951 DOI: https://doi.org/10.1002/ana.24951
Park SB, Goldstein D, Krishnan AV., Lin CSY, Friedlander ML, Cassidy J, et al. Chemother-apy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–37.
https://doi.org/10.3322/caac.21204 DOI: https://doi.org/10.3322/caac.21204
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Pre-vention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.
https://doi.org/10.1200/JCO.2013.54.0914 DOI: https://doi.org/10.1200/JCO.2013.54.0914
de Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26(1):44–53.
https://doi.org/10.1200/JCO.2007.11.3787 DOI: https://doi.org/10.1200/JCO.2007.11.3787
Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophos-phamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–7.
https://doi.org/10.1200/JCO.2006.06.5391 DOI: https://doi.org/10.1200/JCO.2006.06.5391
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Impro-ved outcomes from adding sequential paclitaxel but not from escalating doxoru-bicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–83.
https://doi.org/10.1200/JCO.2003.02.063 DOI: https://doi.org/10.1200/JCO.2003.02.063
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonme-tastatic breast cancer. J Oncol Pract. 2013;9(5):e234–40.
https://doi.org/10.1200/JOP.2012.000863 DOI: https://doi.org/10.1200/JOP.2012.000863
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer. 2012;20(10):2433–9.
https://doi.org/10.1007/s00520-011-1365-8 DOI: https://doi.org/10.1007/s00520-011-1365-8
Osmani K, Vignes S, Aissi M, Wade F, Milani P, Lévy BI, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259(9):1936–43.
https://doi.org/10.1007/s00415-012-6442-5 DOI: https://doi.org/10.1007/s00415-012-6442-5
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325–48.
https://doi.org/10.1200/JCO.20.01399 DOI: https://doi.org/10.1200/JCO.20.01399
Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose inten-sity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203–10.
https://doi.org/10.1016/j.critrevonc.2014.10.006 DOI: https://doi.org/10.1016/j.critrevonc.2014.10.006
Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–33.
https://doi.org/10.1007/s10549-016-3939-0 DOI: https://doi.org/10.1007/s10549-016-3939-0
Kandula T, Farrar MA, Cohn RJ, Mizrahi D, Carey K, Johnston K, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer cli-nical, neurophysiological, functional, and patient-reported outcomes. JAMA Neu-rol. 2018;75(8):980–8.
https://doi.org/10.1001/jamaneurol.2018.0963 DOI: https://doi.org/10.1001/jamaneurol.2018.0963
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(Suppl.4):iv45–54.
https://doi.org/10.1093/neuonc/nos203 DOI: https://doi.org/10.1093/neuonc/nos203
Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pat-hophysiological mechanisms, and risk factors of chemotherapy-induced pe-ripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86.
https://doi.org/10.3389/fphar.2017.00086 DOI: https://doi.org/10.3389/fphar.2017.00086
Hilkens PHE, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of se-vere peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol. 1997;8(2):187–90.
https://doi.org/10.1023/A:1008245400251 DOI: https://doi.org/10.1023/A:1008245400251
Eckhoff L, Knoop A, Jensen M, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292–300.
https://doi.org/10.1016/j.ejca.2014.11.024 DOI: https://doi.org/10.1016/j.ejca.2014.11.024
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence, preva-lence, and predictors of chemotherapy-induced peripheral neuropathy: a syste-matic review and meta-analysis. Pain. 2014;155(12):2461–70.
https://doi.org/10.1016/j.pain.2014.09.020 DOI: https://doi.org/10.1016/j.pain.2014.09.020
Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–47.
https://doi.org/10.2147/CMAR.S44261 DOI: https://doi.org/10.2147/CMAR.S44261
Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75(4):659–70.
https://doi.org/10.1007/s00280-014-2607-5 DOI: https://doi.org/10.1007/s00280-014-2607-5
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neuro-toxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77.
https://doi.org/10.1016/j.critrevonc.2011.04.012 DOI: https://doi.org/10.1016/j.critrevonc.2011.04.012
de Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34–45.
https://doi.org/10.1016/j.critrevonc.2015.04.011 DOI: https://doi.org/10.1016/j.critrevonc.2015.04.011
Covidence systematic review software [Internet]. Melbourne: Veritas Health Innovation. Available from: www.covidence.org [Cited date: 10/2022]
Munn Z, Sandeep M, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systema-tic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.
https://doi.org/10.1097/XEB.0000000000000054 DOI: https://doi.org/10.1097/XEB.0000000000000054
Lee KM, Jung D, Hwang H, Son KL, Kim TY, Im SA, et al. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. J Psychosom Res. 2018;108:14–19.
https://doi.org/10.1016/j.jpsychores.2018.02.012 DOI: https://doi.org/10.1016/j.jpsychores.2018.02.012
Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, et al. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer. Breast J. 2020;26(12):2376–82.
https://doi.org/10.1111/tbj.14123 DOI: https://doi.org/10.1111/tbj.14123
Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110(6):669–76.
https://doi.org/10.1093/jnci/djx259 DOI: https://doi.org/10.1093/jnci/djx259
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, et al. Final analysis of the pro-spective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014;25(8):1551–7.
https://doi.org/10.1093/annonc/mdu186 DOI: https://doi.org/10.1093/annonc/mdu186
Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, et al. A pilot study of minocy-cline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25(11):3407–16.
https://doi.org/10.1007/s00520-017-3760-2 DOI: https://doi.org/10.1007/s00520-017-3760-2
Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G, et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer. 2007;7(7):550–4.
https://doi.org/10.3816/CBC.2007.n.010 DOI: https://doi.org/10.3816/CBC.2007.n.010
Thornton LM, Carson WE, Shapiro CL, Farrar WB, Andersen BL. Delayed emotional reco-very after taxane-based chemotherapy. Cancer. 2008;113(3):638–47.
https://doi.org/10.1002/cncr.23589 DOI: https://doi.org/10.1002/cncr.23589
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012;20(12):3355–64.
https://doi.org/10.1007/s00520-012-1492-x DOI: https://doi.org/10.1007/s00520-012-1492-x
Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, et al. Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist. 2021;26(5):366–74.
https://doi.org/10.1002/onco.13697 DOI: https://doi.org/10.1002/onco.13697
Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study. J Natl Cancer Inst. 2017;109(2):djw206.
https://doi.org/10.1093/jnci/djw206 DOI: https://doi.org/10.1093/jnci/djw206
Martín M, Rodríguez-Lescure Á, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805–14.
https://doi.org/10.1093/jnci/djn151 DOI: https://doi.org/10.1093/jnci/djn151
Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, et al. Can pregabalin pre-vent paclitaxel-associated neuropathy? – an ACCRU pilot trial. Support Care Can-cer. 2016;24(2):547–53.
https://doi.org/10.1007/s00520-015-2807-5 DOI: https://doi.org/10.1007/s00520-015-2807-5
Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132–8.
https://doi.org/10.1007/s10147-011-0352-x DOI: https://doi.org/10.1007/s10147-011-0352-x
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767–74.
https://doi.org/10.1007/s10549-010-1278-0 DOI: https://doi.org/10.1007/s10549-010-1278-0
Ng DQ, Tan CJ, Soh BC, Tan MML, Loh SY, Tan YE, et al. Impact of cryotherapy on sensory, motor, and autonomic neuropathy in breast cancer patients receiving paclitaxel: a randomized, controlled trial. Front Neurol. 2020;11:604688.
https://doi.org/10.3389/fneur.2020.604688 DOI: https://doi.org/10.3389/fneur.2020.604688
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemot-herapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2):djx162.
https://doi.org/10.1093/jnci/djx162 DOI: https://doi.org/10.1093/jnci/djx162
Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, vander Woude AC, et al. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced pe-ripheral neuropathy (RU221511I); an ACCRU trial. Breast. 2019;48:89–97.
https://doi.org/10.1016/j.breast.2019.09.011 DOI: https://doi.org/10.1016/j.breast.2019.09.011
Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer. 2020;28(9):4163–72.
https://doi.org/10.1007/s00520-019-05254-6 DOI: https://doi.org/10.1007/s00520-019-05254-6
Park SB, Goldstein D, Lin CSY, Krishnan AV., Friedlander ML, Kiernan MC. Acute abnorma-lities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009;27(8):1243–9.
https://doi.org/10.1200/JCO.2008.19.3425 DOI: https://doi.org/10.1200/JCO.2008.19.3425
Fukuda Y, Li Y, Segal RA. A mechanistic understanding of axon degeneration in chemot-herapy-induced peripheral neuropathy. Front Neurosci. 2017;11:481.
https://doi.org/10.3389/fnins.2017.00481 DOI: https://doi.org/10.3389/fnins.2017.00481
Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology. 2014;76(Pt A):175–83.
https://doi.org/10.1016/j.neuropharm.2013.08.016 DOI: https://doi.org/10.1016/j.neuropharm.2013.08.016
Duggett NA, Griffiths LA, McKenna OE, de Santis V, Yongsanguanchai N, Mokori EB, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience. 2016;333:13–26.
https://doi.org/10.1016/j.neuroscience.2016.06.050 DOI: https://doi.org/10.1016/j.neuroscience.2016.06.050
Park SB, Lin CSY, Krishnan AV, Friedlander ML, Lewis CR, Kiernan MC. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuro-pathy. Muscle Nerve. 2011;43(3):367–74.
https://doi.org/10.1002/mus.21874 DOI: https://doi.org/10.1002/mus.21874
Haryani H, Fetzer SJ, Wu CL, Hsu YY. Chemotherapy-induced peripheral neuropathy as-sessment tools: a systematic review. Oncol Nurs Forum. 2017;44(3):E111–23.
https://doi.org/10.1188/17.ONF.E111-E123 DOI: https://doi.org/10.1188/17.ONF.E111-E123
McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, et al. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer. 2017;25(11):3485–93.
https://doi.org/10.1007/s00520-017-3772-y DOI: https://doi.org/10.1007/s00520-017-3772-y
Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132.
https://doi.org/10.1186/s12885-019-5302-4 DOI: https://doi.org/10.1186/s12885-019-5302-4
Griffith KA, Merkies ISJ, Hill EE, Cornblath DR. Measures of chemotherapy-induced pe-ripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2010;15(4):314–25.
https://doi.org/10.1111/j.1529-8027.2010.00292.x DOI: https://doi.org/10.1111/j.1529-8027.2010.00292.x
Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D. Chemotherapy-induced peripheral neuropathy – patient-reported outcomes compared with NCI-CTCAE grade. Sup-port Care Cancer. 2019;27(12):4771–7.
https://doi.org/10.1007/s00520-019-04781-6 DOI: https://doi.org/10.1007/s00520-019-04781-6
Olver I, Carey M, Boyes A, Hall A, Noble N, Bryant J, et al. The timeliness of patients repor-ting the side effects of chemotherapy. Support Care Cancer. 2018;26(10):3579–86.
https://doi.org/10.1007/s00520-018-4225-y DOI: https://doi.org/10.1007/s00520-018-4225-y
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Coch-rane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019. DOI: https://doi.org/10.1002/9781119536604
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Freja L. Kruse, Margrethe B. Bille, Maria E. Lendorf, Susan Vaabengaard, Steffen Birk
This work is licensed under a Creative Commons Attribution 4.0 International License.
